Is diarrhoea a manifestation of rheumatoid arthritis in a 39‑year‑old woman taking tofacitinib 5 mg twice daily, methotrexate 15 mg weekly, and hydroxychloroquine 400 mg daily?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Is Diarrhea a Manifestation of Rheumatoid Arthritis in This Patient?

Diarrhea is not a manifestation of rheumatoid arthritis itself, but is a well-documented adverse effect of tofacitinib, one of the medications this patient is taking.

Diarrhea and Rheumatoid Arthritis

  • Rheumatoid arthritis does not cause diarrhea as a disease manifestation 1
  • The primary manifestations of RA are joint inflammation (arthritis), morning stiffness, and systemic symptoms such as fatigue, but gastrointestinal symptoms are not part of the disease presentation 1

Medication-Related Diarrhea in This Patient

Tofacitinib as the Likely Culprit

  • Tofacitinib is associated with gastrointestinal side effects, including diarrhea, which is one of the most common adverse events reported with this JAK inhibitor 2
  • In clinical trials, gastrointestinal adverse events including diarrhea were documented in patients receiving tofacitinib for rheumatoid arthritis 3, 4, 5
  • The safety profile of tofacitinib includes gastrointestinal disturbances as a recognized adverse effect 6

Methotrexate Contribution

  • Methotrexate commonly causes gastrointestinal side effects, with nausea being the most frequent (occurring in up to 25% of patients), but diarrhea can also occur 7
  • Gastrointestinal problems were reported in 30% of patients receiving methotrexate in one study 6
  • These gastrointestinal effects are dose-dependent and typically occur within 12-24 hours of medication administration 7

Hydroxychloroquine Consideration

  • Hydroxychloroquine is generally well-tolerated and is less commonly associated with significant gastrointestinal side effects compared to tofacitinib or methotrexate 8, 9
  • It is considered compatible with breastfeeding and has a favorable safety profile 8

Clinical Approach to This Patient

Immediate Assessment

  • Evaluate the timing of diarrhea onset relative to medication initiation or dose changes, particularly focusing on when tofacitinib was started 2
  • Assess severity, frequency, and associated symptoms (fever, blood, weight loss) to rule out infectious causes or other serious complications 10
  • Consider that tofacitinib increases the risk of infections, including gastrointestinal infections, which could present with diarrhea 3, 5

Management Strategy

  • If diarrhea is mild and medication-related, supportive care and monitoring may be sufficient 2
  • For persistent or severe diarrhea attributed to tofacitinib, consider dose reduction or switching to an alternative therapy such as a TNF inhibitor or IL-17 inhibitor 11
  • If methotrexate is contributing, ensure adequate folic acid supplementation (at least 5 mg weekly) which can reduce gastrointestinal toxicity 7, 12
  • Rule out opportunistic infections, particularly cytomegalovirus colitis in immunosuppressed patients, though this is more relevant in inflammatory bowel disease 10

Key Clinical Pitfall to Avoid

  • Do not attribute diarrhea to the underlying rheumatoid arthritis disease process, as RA does not cause gastrointestinal manifestations 1
  • Always consider medication adverse effects first in a patient on multiple immunosuppressive agents 2, 7
  • Do not overlook infectious causes, as this patient is on triple immunosuppression (tofacitinib, methotrexate, and hydroxychloroquine), which increases infection risk 3, 6, 5

References

Research

Tofacitinib versus methotrexate in rheumatoid arthritis.

The New England journal of medicine, 2014

Guideline

Methotrexate in Rheumatoid Arthritis: Efficacy and Toxicity Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.